Located on Chromosome 1, this mutation impacts TARS2 (threonyl-tRNA synthetase 2, mitochondrial). What is its biological consequence — is it benign or pathogenic, and which disease is associated if any?
Pathogenic; Combined oxidative phosphorylation defect type 21